AbCellera Biologics (ABCL) 2024 Cantor Fitzgerald Global Healthcare Conference summary

Company overview and strategy

• Focuses on antibody discovery and development, evolving from fee-for-service to royalty, co-development, and wholly owned programs over 12 years.

• Built integrated capabilities from target identification to clinical manufacturing, enabling both internal and partnered programs.

• Strategic partnerships with major pharma companies like Eli Lilly, Regeneron, and Biogen have validated technology and expanded collaboration scope.

• Emphasizes advancing internal pipeline, with two wholly owned programs entering the clinic next year.

• Pursues company creation ventures, taking equity and royalty positions to enhance near-term and long-term value.

Key partnerships and collaborations

• Expanded Eli Lilly partnership to cover additional antibody targets, reflecting strong ongoing relationships.

• New collaborations in T-cell engager space and with Biogen, with potential for further manufacturing and development partnerships.

• Manufacturing capabilities (CMC and GMP) being built to support both internal and partner programs, with first batches expected in the next year.

• Strategic partnerships have led to 13 molecules in clinical development using company technology.

Internal pipeline and product development

• Over 100 royalty positions established, with a shift toward higher-value co-development and wholly owned assets.

• Two lead programs, ABCL-635 (first-in-class for metabolic/endocrine) and ABCL-575 (OX40 ligand for atopic dermatitis), entering IND-enabling studies and expected in clinic next year.

• ABCL-575 offers potential differentiation via dosing frequency; ABCL-635 targets a $2B+ market with clear clinical path.

• Additional development candidates to be announced as pipeline progresses.